Architect hbsag

A total of 80 samples were collected from patients (68 males and 12 females; median age, 51; age range, 26–72) at The First Affiliated Hospital of Dalian Medical University (Dalian, China) from 2010 to 2014. Tumor tissue (TT) and adjacent non-tumor tissue (ANT) were resected by surgical excision. Clinicopathological data were obtained from archived medical records. The records included patient gender, age, size of tumor, vascular invasion, tumor number, liver cirrhosis, Child-Pugh grade, hepatitis B surface antigen (HBsAg), α-fetoprotein (AFP), histological grade, and pathological stage. The liver cirrhosis was diagnosed by pathology, and the Child-Pugh grade was divided into three grades according to evaluation indexes, including hepatic encephalopathy, ascites, bilirubin, albumin and prothrombin time. Serum HBsAg was detected using ARCHITECT HBsAg (Abbott Laboratories, Chicago, IL, USA) and AFP was determined using Elecsys and Cobas analyzers (Roche Diagnostics). The histological grade was determined according to Edmondson-Steiner modification, and pathological staging was determined according to the seventh edition of the tumor node metastasis (TNM) classification of the International Union Against Cancer (19 (link)). Patient consent and approval from the Institutional Research Ethics Committee were obtained prior to the use of these clinical materials for research purposes.

Samples showing discrepant results for ELCIA and AFIAS to detect HBsAg, anti-HBs, and anti-HCV were additionally tested using the Elecsys HBsAg Confirmatory Test (an independent neutralization test with human anti-HBs; Roche Diagnostics GmbH), ARCHITECT Anti-HBs (Abbott Laboratories, Abbott Park, IL, USA), and Deciscan HCV Plus (Bio-Rad Laboratories, Los Angeles, CA, USA), respectively. The Deciscan HCV PLUS assay is a line immunoassay using specific recombinant and peptide antigens (Core, NS3, NS4) to validate anti-HCV seropositivity. Indeterminate results from confirmatory tests were excluded from statistical analysis. For samples with discrepant results, clinical diagnoses were reviewed to confirm the results. To compare assays using seroconversion panels, Elecsys HBsAg II, ARCHITECT HBsAg (Abbott Laboratories), Elecsys anti-HCV II, and ARCHITECT anti-HCV (Abbott Laboratories) assays were used. All tests were performed and interpreted according to the manufacturer's instructions.

Serum samples collected from the study children were tested by commercial ELISA kits for HBsAg, antibody to HBsAg (anti-HBs), HBeAg, antibody to HBeAg (anti-HBe), and antibody to HBV core antigen (anti-HBc) at Nanjing Drum Tower Hospital. HBsAg was tested with an ELISA kit (Huakang Biotech, Shenzhen, China) or microparticle enzyme immunoassay (Architect HBsAg, Abbott, North Chicago, USA). Anti-HBs and HBeAg were quantified with a microparticle enzyme immunoassay (AxSYM AUSAB, Abbott).
HBV DNA levels were measured in mothers during pregnancy by fluorescent quantitative polymerase chain reaction (PCR) with a lower detection limit of 100 IU/ml (Shenyou Biotech, Shanghai, China).